El virus influenza y la gripe aviar
DOI:
https://doi.org/10.51481/amc.v50i1.346Palabras clave:
Influenza A, gripe aviar, pandemia, H5N1Resumen
En este artículo se presenta una revisión del virus influenza, su biología, sus mecanismos de variación antigénica, las pandemias que ha producido y la prevención mediante las vacunas y medicamentos antivirales. Se analizan las razones por las cuales aparece el virus H5N1 que produce la fiebre aviar en humanos, la patogénesis de este virus y las estrategias para su prevención. Se informa sobre el plan de preparación para la pandemia en los niveles nacional e internacional.
Descargas
Citas
Webster RG. Influenza: An Emerging Disease. Emerg Infect Dis 1998;4:1-7.
Murphy BR & Webster RG.. Orthomyxovirus. En: Virology. Fields BN et al (ed). Lippincott-Raven Publishers. 1996. pp.1397-1445
Kuiken T, Holmes EC, McCauley J, Rimmelzwaan GF Williams C.S. Grenfell B.T. Host species barriers to Influenza Virus Infections. Science 2006; 312:4-13.
Yamada Sh, Suzuki Y, Suzuqui T, Le M, Nidom ch, Sakai Y, et al. Haemagglutinin mutations responsable for the binding of H5N1 influenza A virases to human-type receptors. Nature. 2006; 444:378382.
Webster R. G. Peiris M, Chen H, Guan Y. H5N1 Outbreaks and Enzootic Influenza Emerg Infect Dis 2006;12:3-8.
Palese P. Making Better Influenza Virus Vaccines? Emerg Infect Dis 2006; 12:61-64.
Taubenberger JK & Morens, DM. 1918 Influenza: the Mother of All Pandemics. Emerg Infect Dis 2006; 12: 1-12.
Johnson NP, Mueller J. Updating the accounts: global mortality of the 1918-1920 “Spanish” influenza pandemic. Bull Hist Med 2002; 76:105-15
Kobasa D, Takada A, Shinya K, Hatta M, Halfmann P, Theriault S, et al. Enhanced virulence of Influenza A viruses with the haemagglutinin of the 1918 pandemic virus. Nature 2004; 431:703-701.
Reid AH, Fanning TG, Hultin JV, Taubenberger JK. Origen and evolution of the 1918 “Spanish” influenza virus hemagglutinin gene. Proc Nalt Acad Sci USA 1999; 96:1651-56.
Kilbourne ED. Influenza Pandemics of the 20th Century. Emerg Infect Dis. 2006;12:9-14
Dowdle WR. Influenza Pandemic Periodicity, Virus Recycling and the Art of Risk Assessment. Emerg Infect Dis 2006;12:34-39.
Karasin AI, Olsen CW, Anderson GA. Genetic characterization of an H1N2 influenza virus isolated from a pig in Indiana. J Clin Microbiol. 2000;38:2453–6.
Yeun KY, Wong SSY. Human Infection by avian influenza A H5N1. Hong Kong Med J. 2005;11:189-199.
Liu J, Xiao H, Lei F, Zhu Q, Qin K, Zang X-W et al. Highly Pathogenic H5N1! Influenza Virus Infection in Migratory Birds. 2005; Science 309:1206.
Webster R G. Wet markets- continuing source of severe acute respiratory syndrome and Influenza? Lancet. 2004;363:234
Halvorson S. Avian Influenza. Disponible en: www.cvm.umn.edu/ai_ old/home.html
Luke CJ & Subbaroa K. Vaccines for Pandemic Influenza. Emerg Infect Dis 2006; 12:66-72.
Kuiken T, Rimmelzwaan G, van Riel D, van Amerongen G, Baars M, Fouchier R et al. Avian H5N1 influenza in cats. Science 2004;306: 241.
Shinyal K, Ebina M, Yamada Sh, Ono M, Kasai N, Kawaoka Y, et al. Avian flu: Influenza virus receptors in the human airway. Nature 2006; 440: 435.
Olsen B, Munster VJ, Wallensten A, Waldenstrom J, Osterhaus ADME, Fouchier RAM. Global Patterns of Influenza A virus in Wild Birds. Science. 2006; 312:4-8.
Garcia-Sastre A. Antiviral Response in Pandemic Influenza Viruses. Emerg Infect Dis 2006;12:44-7.
Thomas PG, Keating R, Hulse-Post DJ, Doherty PC. Cell-Mediated Protection in Influenza Infection. Emerg Infect Dis. 2006;12:48-54.
Quirk M. H5N1 genes show avian origins and drifting. Emerg Infect Dis 2005; 11: 1510-21.
Stephenson I, Bugarini R. Nicholson KG, Podda a, Wood JM Zambon MC, Katz JM. Cross-Reactivity to highly Pathogenic Avian Influenza
H5N1 Viruses after Vaccination with Nonadjuvant and MF59Adjuvantes Influenza A/Duck/Singapore/97 (H5N3) Vaccine: A Potential Priming Strategy. JID 2005;191:1210-5
Yang ZY, Wei ChJ, Kong WP, Wu L, Xu L Smith D.F. Nabel GJ. Immunization by Avian H5 Influenza Hemagglutinin Mutants with Altered Receptor Binding Specificity. Science 2007; 317:825-8.
Taubenberger JK, Reid A.H. & Fanning TG. Capturing a Killer Flu virus. Scientific American. 2005. pp. 62-71.
Stephenson I, Gust I, Pervikov Y, Kieny MP. Development of vaccines against influenza H5. Lancet Infect Dis. 2006; 6:458-9.
Influenza pandemic preparation—much still to be done. Lancet Infect Dis 2006; 6: 315.
Stephenson I, Gust I, Pervikov Y, Kieny MP. Development of vaccines against influenza H5. Lancet Infect Dis 2006; 6:458-9.
Gani, R, Hughes H, Fleming D, Griffin T, Medlock J, Leach S. Potential Impact of Antiviral Drug Use during Influenza Pandemic. Emerging Infectious Diseases 2006; 11:1-13.
Katz JM, Lim W, Bridges CB, et al. Antibody response in individuals infected with avian influenza A (H5N1) viruses and detection of antiH5 antibody among household and social contacts. J Infect Dis 1999;180:1763-70.
Buxton Briges C, Katz JM, Seto WH, et al. Risk of influenza A (H5N1) infection among health care workers exposed to patients with influenza A (H5N1), Hong Kong. J Infect Dis. 2000;181:344-8.
Seo SH, Hoffmann E, Webster RG. Lethal H5N1 influenza viruses escape host anti-viral cytokine responses. Nat Med 2002,8:950-4.
Cheung CY, Poon LL, Lau AS, Shortridge KF, Gordon S, Guan Y, et al. Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease? Lancet 2002; 360:1831-7.
Peiris JS, Yu WC, Leung CW, Cheung CY, Ng WF, Nicholls JM, et al. Re-emergence of fatal human influenza type A subtype H5N1 disease. Lancet 2004; 363:617-9.
Bonn D. Wild birds, poultry, and avian influenza. Lancet Infect Dis 2006;6:262
Secretaría de Salud. Acciones Básicas ante una Pandemia de Influenza. Boletín de Práctica Médica Efectiva. Diciembre 2006.
Yang Y, Halloran ME, Sugimoto J, Longini, Jr IM. Detecting human-to-human transmission of avian influenza A (H5N1). Disponible en: http://www.cdc.gov/EID/content/13/9/1348.htm>
Herrero, L. Alfaro, W. Virus Influenza circulantes en Costa Rica 1998 – 2001. ¿Cuándo vacunar? Acta Médica Pediátrica 16(3):111115,2002.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2008 Acta Médica Costarricense
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
Los autores que publican en la revista Acta Médica Costarricense pueden distribuir, copiar, remezclar, retocar, leer, descargar, imprimir, buscar y crear a partir de su obra de modo no comercial, indicando los créditos a la revista y sus autores y compartir su obra en las mismas condiciones. Para ello se aplica la licencia Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0 Internacional(CC BY-NC-SA 4.0)
